Wells Fargo & Company Verona Pharma PLC Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Verona Pharma PLC stock. As of the latest transaction made, Wells Fargo & Company holds 80,822 shares of VRNA stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80,822
Previous 60,191
34.28%
Holding current value
$2.41 Million
Previous $968,000
20.66%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VRNA
# of Institutions
137Shares Held
66.7MCall Options Held
495KPut Options Held
486K-
Ra Capital Management, L.P. Boston, MA7.63MShares$227 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$166 Million7.62% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$119 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$106 Million7.58% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.31MShares$98.7 Million2.82% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $1.82B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...